MedCity News December 11, 2023
Frank Vinluan

Novartis drug iptacopan, which won its first FDA approval in early December in a rare blood disorder, has met the main goal of a pivotal test in an ultra-rare kidney disease. The small molecule’s potential to address many diseases has stirred up blockbuster expectations.

The blockbuster potential for new Novartis drug iptacopan rests on the molecule’s ability to reach many diseases. The drug is on the way to its first one, following a recent FDA approval in a rare blood disorder. Now Novartis has data in a different rare disease with no approved treatment options. The Swiss pharmaceutical giant says these results could support regulatory submissions in 2024.

While Novartis has said iptacopan could achieve peak sales topping $3 billion,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article